Details of the Drug

General Information of Drug (ID: DM3ZW6A)

Drug Name
VAN-10-4-eluting stent
Synonyms INC-105-eluting stent, Inncardio/University of Strathclyde; VAN-10-4-eluting stent, University of Strathclyde; Marigold compound (drug-eluting stent, restenosis), Inncardio/University of Strathclyde
Indication
Disease Entry ICD 11 Status REF
Artery stenosis BD52 Phase 1 [1]
Cross-matching ID
TTD ID
D08KNG

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Extracellular signal-regulated kinase 1 (ERK1) TT1MG9E MK03_HUMAN Inhibitor [2]
Extracellular signal-regulated kinase 2 (ERK2) TT4TQBX MK01_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Artery stenosis
ICD Disease Classification BD52
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Extracellular signal-regulated kinase 2 (ERK2) DTT MAPK1 6.78E-05 1.12 2.73
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drug-Eluting Stent for High Risk Patients. University of Strathclyde Glasgow. 2015
2 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
3 DOI: 10.1158/1538-7445.AM2015-4693
4 Clinical pipeline report, company report or official report of HaiHe Biopharma.
5 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
6 ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
7 National Cancer Institute Drug Dictionary (drug name JSI1187).
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
10 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
11 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
12 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
13 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.